Related Experiment Video
Updated: Feb 14, 2026

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids
Published on: August 18, 2023
Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma
Thomas T DeLeon1, Daniel H Ahn1, James M Bogenberger1
1Division of Hematology Oncology, Department of Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA.
Abstract:
Worldwide hepatobiliary cancers are the second leading cause of cancer related death. Despite their relevance, hepatobiliary cancers have a paucity of approved systemic therapy options. However, there are a number of emerging therapeutic biomarkers and therapeutic concepts that show promise. In hepatocellular carcinoma, nivolumab appears particularly promising and recently received US FDA approval. In intrahepatic cholangiocarcinoma, therapies targeting FGFR2 and IDH1 and immune checkpoint inhibitors are the furthest along and generating the most excitement. There are additional biomarkers that merit further exploration in hepatobiliary cancers including FGF19, ERRFI1, TERT, BAP1, BRAF, CDKN2A, tumor mutational burden and ERBB2 (HER2/neu). Development of new and innovative therapies would help address the unmet need for effective systemic therapies in advanced and metastatic hepatobiliary cancers.
Insights
Hepatobiliary cancers cause many deaths globally, with limited treatments. Emerging biomarkers and therapies, like nivolumab for hepatocellular carcinoma and FGFR2/IDH1 targets for cholangiocarcinoma, offer new hope.
Area of Science:
- Oncology
- Gastroenterology
- Cancer Research
Background:
- Hepatobiliary cancers represent a significant global health burden, ranking as the second leading cause of cancer-related mortality worldwide.
- There is a critical unmet need for effective systemic therapies in advanced and metastatic stages of these malignancies.
- Current treatment options for hepatobiliary cancers are limited, highlighting the necessity for novel therapeutic strategies.
Purpose of the Study:
- To review emerging therapeutic biomarkers and innovative treatment concepts for hepatobiliary cancers.
- To highlight promising advancements in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
- To identify additional biomarkers requiring further investigation in the broader category of hepatobiliary cancers.
Main Methods:
- Literature review of recent advancements in systemic therapy for hepatobiliary cancers.
- Analysis of approved and investigational therapies targeting specific molecular pathways and immune checkpoints.
- Identification and categorization of potential biomarkers for therapeutic targeting.
Main Results:
- Nivolumab has shown promise and received US FDA approval for hepatocellular carcinoma.
- Intrahepatic cholangiocarcinoma is seeing advancements with therapies targeting FGFR2, IDH1, and immune checkpoint inhibitors.
- Several biomarkers including FGF19, ERRFI1, TERT, BAP1, BRAF, CDKN2A, tumor mutational burden, and ERBB2 (HER2/neu) warrant further exploration.
Conclusions:
- Emerging biomarkers and novel therapeutic strategies hold significant promise for improving outcomes in hepatobiliary cancers.
- Targeted therapies and immunotherapies represent key areas of development for these challenging diseases.
- Continued research into novel agents and biomarkers is crucial to address the unmet needs in advanced hepatobiliary cancers.
More Related Videos
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Gene Therapy
Group Therapy
Nerve Supply of the GI Tract
The enteric nervous system consists of two major plexuses: the myenteric plexus (Auerbach's plexus) and the submucosal plexus (Meissner's plexus). These plexuses are located within the layers of...